MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) is relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN plus DEX)

被引：0

作者：

Siegel, David Samuel DiCapua

Agajanian, Richy

Gaur, Rakesh

Karamiou, Kasra

Kaya, Hakan

Sturniolo, Michael

Ricafort, Rosanna J.

Larkins, Gall

Srinivasan, Shankar

Chopra, Rajosh

Thakurta, Anjan

Nagarwala, Yasir M.

Kruter, Flavio

机构：

[1] John Theurer Canc Ctr, Hackensack, NJ USA

[2] Oncol Inst Hope & Innovat, Downey, CA USA

[3] St Lukes Canc Inst, Kansas City, MO USA

[4] Bay Area Canc Res Grp, Pleasant Hill, CA USA

[5] Canc Care Northwest, Spokane, WA USA

[6] Celgene Corp, Summit, NJ USA

[7] Carroll Reg Canc Ctr, Westminister, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.tps8627

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8627

引用

页数：1

共 50 条

[31] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Mikhael, Joseph
Richardson, Paul G.
Usmani, Saad Zafar
Raje, Noopur S.
Bensinger, William
Dubin, Franck
Liu, Qianying
Vitse, Olivier
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
Lacy, M. Q.
Hayman, S. R.
Gertz, M. A.
Short, K. D.
Dispenzieri, A.
Kumar, S.
Greipp, P. R.
Lust, J. A.
Russell, S. J.
Dingli, D.
Zeldenrust, S.
Fonseca, R.
Bergsagel, P. L.
Roy, V.
Mikhael, J. R.
Stewart, A. K.
Laumann, K.
Allred, J. B.
Mandrekar, S. J.
Rajkumar, S. V.
Buadi, F.
LEUKEMIA, 2010, 24 (11) : 1934 - 1939
[33] Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M Q Lacy
S R Hayman
M A Gertz
K D Short
A Dispenzieri
S Kumar
P R Greipp
J A Lust
S J Russell
D Dingli
S Zeldenrust
R Fonseca
P L Bergsagel
V Roy
J R Mikhael
A K Stewart
K Laumann
J B Allred
S J Mandrekar
S V Rajkumar
F Buadi
Leukemia, 2010, 24 : 1934 - 1939
[34] Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM)
Lacy, Martha Q.
Gertz, Morie A.
Hayman, Suzanne R.
Short, Kristen Detweiler
Dispenzieri, Angela
Kumar, Shaji
Zeldenrust, Steven R.
Greipp, Philip R.
Lust, John A.
Russell, Stephen J.
Buadi, Francis
Kyle, Robert
Fonseca, Rafael
Bergsagel, Leif
Roy, Vivek
Mikhael, Joseph R.
Stewart, A. Keith
Reeder, Craig B.
Dingli, David
Allred, Jacob
Laumann, Kristina
Mandrekar, Sumithra
Rajkumar, S. Vincent
BLOOD, 2009, 114 (22) : 178 - 178
[35] Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
Siegel, David S.
Schiller, Gary J.
Samaras, Christy J.
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald P.
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Bahlis, Nizar
BLOOD, 2018, 132
[36] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for Res crossover.
Morgan, Gareth J.
San Miguel, Jesus
Dhanasiri, Sujith
Lee, Dawn
Palumbo, Antonio
Facon, Thierry
Zaki, Mohamed H.
Yu, Xin
Sternas, Lars Axel
Jacques, Christian
Weisel, Katja C.
Offner, Fritz
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[37] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
San Miguel, Jesus F.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine I.
Renner, Christoph
Bahlis, Nizar J.
Yu, Xin
Teasdale, Terri
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
BLOOD, 2013, 122 (21)
[38] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
Vij, Ravi
Richardson, Paul Gerard Guy
Jagannath, Sundar
Siegel, David Samuel DiCapua
Baz, Rachid C.
Srinivasan, Shankar
Larkins, Gail
Zaki, Mohamed H.
Hussein, Mohamad A.
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[39] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
San-Miguel, Jesus F.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[40] MM-008: A PHASE 1 TRIAL EVALUATING PHARMACOKINETICS AND TOLERABILITY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH RENAL IMPAIRMENT
Matous, J.
Siegel, D.
Duong, H.
Kasserra, C.
Sternas, L.
Jacques, C.
Klesczewski, K.
Zaki, M.
Shah, J.
HAEMATOLOGICA, 2013, 98 : 323 - 323

← 1 2 3 4 5 →